UNSPSC 51412606: Todralazine hydrochloride

This classification denotes a vasodilating agent with the molecular formula C11H12N4O2.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5998D60YO0, chemically known as ethyl 3-(phthalazin-1-yl)carbazate hydrochloride monohydrate, but more generally known as todralazine hydrochloride, which bears US NIH Compound Identifier 904. European Medicines Agency schedules todralazine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11141MIG.

Most nations, for tariff purposes, schedule todralazine hydrochloride under HS 29339990. SMILES: CCOC(=O)NNC1C2CCCCC2CNN1.O.CL.

UNSPSC 51412606 Todralazine hydrochloride is a Commodity code covering a single pharmaceutical active ingredient used in emergency medical and critical-care settings. State and local governments procure this drug primarily through emergency medical services (EMS) and fire rescue departments as part of advanced life support medication supplies, though it also appears in broader pharmaceutical procurement vehicles serving state health agencies, hospital systems, and multi-jurisdictional cooperative purchasing alliances. Recent solicitations show the code embedded in larger medication bundles rather than as a standalone line item, reflecting how EMS and public health agencies consolidate pharmaceutical purchasing to streamline inventory management, compliance documentation (OSHA Safety Data Sheets, FDA expiration requirements, Good Manufacturing Practice certification), and vendor qualification.

Recent activity spans fire rescue procurement in Florida and multi-state cooperative pharmaceutical contracting. The City of Tampa's Purchasing Department issued an IFB in April 2026 (due April 8, 2026) for Advanced Life Support Medications including four specific cardiac and vasopressor agents for Tampa Fire Rescue in Hillsborough County, with an estimated contract value of $40,000 and a one-year term plus renewal options. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP due March 26, 2026, to establish multi-award contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, requiring vendors to supply through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson). The Texas Health and Human Services Commission posted an RFI in April 2026 exploring direct-to-manufacturer pharmacy contracting for state employee and Medicaid populations, signaling potential future demand consolidation. The code shows modest recent activity concentrated in state health procurement, EMS supplier bases, and cooperative purchasing arrangements rather than broad municipal or county demand.